Ovid Therapeutics Inc.
corporate_fare Company Profile
Ovid Therapeutics Inc. (NASDAQ:OVID) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 15 items for OVID at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 7/10. Across its 15 most recent items scored 7 or higher, the top rating is 8/10, with 6 rated 8 or above. Recent SEC coverage for OVID spans 10-Q, 8-K, 424B3, S-3.
Recent high-impact activity:
- Ovid 10-Q: $20.8M Q3 Loss, $161.4M Cash, Cowen ATM Replaced by $75M Cantor Facility
- Ovid Posts $20.8M Q3 Loss, $161.4M Cash Into 2029, Three Readouts Set for Early 2027
- Ovid Q2 2026: $15M Net Loss, $169.8M Cash, and New Financing Details
- Ovid's Q2 2026: Cash Runway to 2029, OV329 Phase 2 Underway, and a Soticlestat Deal Worth Up to $294.5M
- Ovid Reports $15M Q2 Loss, $169.8M Cash; OV329 Phase 2 Initiated
Financial Snapshot
Short Interest & Short Volume
8.20 days to coverFINRA reported short interest of 18,134,225 shares in OVID as of the October 30, 2026 settlement, a 0.4% increase from the prior period — about 8.2 days to cover at its recent average daily volume. On November 20, 2026, 77.4% of OVID volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for OVID, detected from its recent SEC filings · based on capital-structure filings through 2026-11-10.
Shelf and $75M ATM Registered · Most of Shelf Is Carried Forward
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →